Trade Basilea Pharma AG - BSLN CFD

Add to favourite

40.60

2.52%

0.35

Low: 40.6

High: 41.65

Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 15:20

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.35

Long position overnight fee

-0.014983%

Short position overnight fee

-0.007239%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

CHF

Margin

Stock exchange

Switzerland

Commission on trade

*Information provided by Capital.com

Basilea Pharmaceutica AG Allschwil ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	41.65
Open*	41.35
1-Year Change*	-5.27%
Day's Range*	40.6 - 41.65
52 wk Range	32.00-55.40
Average Volume (10 days)	33.19K
Average Volume (3 months)	539.14K
Market Cap	433.60M
P/E Ratio	7.03
Shares Outstanding	11.98M
Revenue	174.02M
EPS	4.71
Dividend (Yield %)	N/A
Beta	0.98
Next Earnings Date	Feb 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	40.60	-0.55	-1.34%	41.15	41.80	40.45
Apr 18, 2024	41.65	0.35	0.85%	41.30	42.05	41.10
Apr 17, 2024	41.60	0.70	1.71%	40.90	41.70	40.30
Apr 16, 2024	40.50	0.50	1.25%	40.00	41.25	40.00
Apr 15, 2024	40.60	0.30	0.74%	40.30	41.40	40.20
Apr 12, 2024	40.35	-0.15	-0.37%	40.50	41.45	40.05
Apr 11, 2024	40.35	0.15	0.37%	40.20	40.95	39.85
Apr 10, 2024	40.95	0.20	0.49%	40.75	41.45	40.20
Apr 9, 2024	41.00	-0.15	-0.36%	41.15	41.65	40.75
Apr 8, 2024	41.10	-0.90	-2.14%	42.00	42.20	40.85
Apr 5, 2024	42.60	0.15	0.35%	42.45	43.10	41.90
Apr 4, 2024	42.95	1.95	4.76%	41.00	44.30	40.55
Apr 3, 2024	37.40	0.40	1.08%	37.00	38.15	36.25
Apr 2, 2024	37.10	-0.05	-0.13%	37.15	37.90	36.05
Mar 28, 2024	36.80	-0.65	-1.74%	37.45	37.90	36.80
Mar 27, 2024	37.40	0.25	0.67%	37.15	37.65	36.65
Mar 26, 2024	37.40	1.10	3.03%	36.30	37.65	36.30
Mar 25, 2024	36.75	0.25	0.68%	36.50	37.10	36.30
Mar 22, 2024	36.45	1.00	2.82%	35.45	36.85	35.05
Mar 21, 2024	35.40	0.90	2.61%	34.50	35.55	34.05

Basilea Pharma AG Events

Time (UTC)	Country	Event
Wednesday, April 24, 2024
Time (UTC) 12:00	Country CH	Event Basilea Pharmaceutica AG Allschwil Annual Shareholders Meeting Basilea Pharmaceutica AG Allschwil Annual Shareholders Meeting Forecast - Previous -
Thursday, April 25, 2024
Time (UTC) 12:00	Country CH	Event Basilea Pharmaceutica AG Allschwil Annual Shareholders Meeting Basilea Pharmaceutica AG Allschwil Annual Shareholders Meeting Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	147.765	148.122	127.629	134.381	132.555
Revenue	147.765	148.122	127.629	134.381	132.555
Cost of Revenue, Total	24.603	24.072	24.054	18.868	20.299
Gross Profit	123.162	124.05	103.575	115.513	112.256
Total Operating Expense	129.263	147.432	136.165	151.581	156.65
Selling/General/Admin. Expenses, Total	30.815	29.721	29.422	30.051	31.409
Research & Development	73.804	93.157	97.41	102.662	104.942
Operating Income	18.502	0.69	-8.536	-17.2	-24.095
Interest Income (Expense), Net Non-Operating	-9.522	-8.085	-7.485	-6.396	-6.528
Other, Net	3.122	0.601	1.354	1.214	-0.537
Net Income Before Taxes	12.102	-6.794	-14.667	-22.382	-31.16
Net Income After Taxes	12.147	-6.831	-14.722	-22.422	-31.352
Net Income Before Extra. Items	12.147	-6.831	-14.722	-22.422	-31.352
Net Income	12.147	-6.831	-14.722	-22.422	-31.352
Income Available to Common Excl. Extra. Items	12.147	-6.831	-14.722	-22.422	-31.352
Income Available to Common Incl. Extra. Items	12.147	-6.831	-14.722	-22.422	-31.352
Diluted Net Income	12.147	-6.831	-14.722	-22.422	-31.352
Diluted Weighted Average Shares	11.861	11.682	10.2815	10.7557	10.8379
Diluted EPS Excluding Extraordinary Items	1.02412	-0.58475	-1.43189	-2.08466	-2.89281
Dividends per Share - Common Stock Primary Issue	0	0	0	0	0
Diluted Normalized EPS	1.02636	-0.55793	-2.36256	-2.08466	-2.89281
Unusual Expense (Income)	0.041	0.482	-14.721
Other Operating Expenses, Total	0

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total revenue	84.905	89.118	57.647	93.924	54.198
Revenue	84.905	89.118	57.647	93.924	54.198
Cost of Revenue, Total	9.996	9.684	14.919	10.547	13.525
Gross Profit	74.909	79.434	42.728	83.377	40.673
Total Operating Expense	48.007	61.531	67.732	77.624	69.808
Selling/General/Admin. Expenses, Total	16.544	15.194	15.621	15.382	14.339
Research & Development	21.467	36.656	37.148	51.468	41.689
Operating Income	36.898	27.587	-10.085	16.3	-15.61
Interest Income (Expense), Net Non-Operating	-5.307	-5.773	-3.749	-4.01	-4.075
Other, Net	0.276	2.509	1.613	0.793	-0.192
Net Income Before Taxes	31.867	24.323	-12.221	13.083	-19.877
Net Income After Taxes	31.84	24.356	-12.209	13.06	-19.891
Net Income Before Extra. Items	31.84	24.356	-12.209	13.06	-19.891
Net Income	31.84	24.356	-12.209	13.06	-19.891
Income Available to Common Excl. Extra. Items	31.84	24.356	-12.209	13.06	-19.891
Income Available to Common Incl. Extra. Items	31.84	24.356	-12.209	13.06	-19.891
Diluted Net Income	31.84	24.356	-12.209	13.06	-19.891
Diluted Weighted Average Shares	11.9781	11.8828	11.8391	11.7986	11.5653
Diluted EPS Excluding Extraordinary Items	2.65818	2.04969	-1.03124	1.10691	-1.71988
Dividends per Share - Common Stock Primary Issue	0	0	0	0	0
Diluted Normalized EPS	2.65818	2.04952	-1.02883	1.12612	-1.70555
Unusual Expense (Income)	0	-0.003	0.044	0.227	0.255
Other Operating Expenses, Total		0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	175.364	241.066	223.528	184.86	274.738
Cash and Short Term Investments	84.659	148.7	161.772	129.024	223.034
Cash	34.7	53.7	50.1	52.5	37.4
Cash & Equivalents	49.959	0	10.649	56.524	135.634
Short Term Investments	0	95	101.023	20	50
Total Receivables, Net	61.704	64.447	32.394	28.295	34.719
Accounts Receivable - Trade, Net	33.152		8.71	6.242	3.757
Total Inventory	24.244	22.783	21.192	18.569	14.411
Other Current Assets, Total	4.757	5.136	8.17	8.972	2.574
Total Assets	220.848	247.267	229.794	221.467	281.751
Property/Plant/Equipment, Total - Net	21.571	2.923	5.275	5.162	6.424
Property/Plant/Equipment, Total - Gross	30.294	17.505	29.348	44.2	45
Accumulated Depreciation, Total	-10.3	-14.6	-24.1	-39	-38.6
Intangibles, Net	0.578	0.632	0.672	0.372	0.372
Long Term Investments			0	30	0
Other Long Term Assets, Total	22.069	0.256	0.319	1.073	0.217
Total Current Liabilities	74.85	174.408	50.161	75.494	66.684
Accounts Payable	0.191	10.617	13.151	6.765	6.399
Accrued Expenses	27.859	33.453	29.052	29.3	26.7
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	9.333	6.833	7.958	39.429	33.585
Total Liabilities	241.563	305.874	331.84	314.427	348.438
Total Long Term Debt	131.36	94.544	239.668	197.74	196.982
Long Term Debt	131.36	94.544	239.668	197.74	196.982
Other Liabilities, Total	35.353	36.922	42.011	41.193	84.772
Total Equity	-20.715	-58.607	-102.046	-92.96	-66.687
Common Stock	13.093	12.992	11.922	11.882	11.879
Retained Earnings (Accumulated Deficit)	26.048	6.577	-33.95	-74.324	-55.05
Treasury Stock - Common	-56.071	-56.559	-52.766	-5.963	-7.235
Other Equity, Total	-3.785	-21.617	-27.252	-24.555	-16.281
Total Liabilities & Shareholders’ Equity	220.848	247.267	229.794	221.467	281.751
Total Common Shares Outstanding	11.9513	11.842	10.8673	10.7739	10.7447
Note Receivable - Long Term	1.266	2.39
Current Port. of LT Debt/Capital Leases	37.467	123.505

	Jun 2023	Dec 2022	Jun 2022	Dec 2021	Jun 2021
Total Current Assets	185.825	175.364	211.789	241.066	220.189
Cash and Short Term Investments	87.714	84.659	140.736	148.7	162.849
Cash & Equivalents	87.714	84.659	45.746	53.7	82.849
Short Term Investments		0	94.99	95	80
Total Receivables, Net	64.384	61.704	38.606	64.447	29.451
Accounts Receivable - Trade, Net	39.669	33.152	10.946		6.618
Total Inventory	25.638	24.244	24.754	22.783	20.94
Other Current Assets, Total	8.089	4.757	7.693	5.136	6.949
Total Assets	230.034	220.848	236.073	247.267	227.176
Property/Plant/Equipment, Total - Net	21.65	21.571	21.619	2.923	3.767
Property/Plant/Equipment, Total - Gross	32.693	30.294	36.044	17.505	20.772
Accumulated Depreciation, Total	-11	-10.3	-14.4	-14.6	-17
Intangibles, Net	0.534	0.578	1.247	0.632	0.467
Long Term Investments
Other Long Term Assets, Total	22.025	22.069	0.152	0.256	0.363
Total Current Liabilities	67.185	74.85	155.443	174.408	37.707
Accounts Payable	3.942	0.191	4.706	10.617	5.378
Accrued Expenses	17.994	27.859	23.709	33.453	25.235
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	7.333	9.333	9.833	6.833	7.094
Total Liabilities	215.045	241.563	303.239	305.874	305.928
Total Long Term Debt	113.179	131.36	94.77	94.544	227.869
Long Term Debt	113.179	131.36	94.77	94.544	227.869
Other Liabilities, Total	34.681	35.353	53.026	36.922	40.352
Total Equity	14.989	-20.715	-67.166	-58.607	-78.752
Common Stock	13.1	13.093	12.999	12.992	12.931
Retained Earnings (Accumulated Deficit)	60.868	26.048	-3.794	6.577	-10.401
Treasury Stock - Common	-55.68	-56.071	-55.865	-56.559	-56.309
Other Equity, Total	-3.299	-3.785	-20.506	-21.617	-24.973
Total Liabilities & Shareholders’ Equity	230.034	220.848	236.073	247.267	227.176
Total Common Shares Outstanding	11.9798	11.9513	11.8512	11.842	11.7932
Current Port. of LT Debt/Capital Leases	37.916	37.467	117.195	123.505
Note Receivable - Long Term	0	1.266	1.266	2.39	2.39

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	12.147	-6.831	-14.722	-22.422	-31.352
Cash From Operating Activities	7.056	-32.02	-54.134	-63.836	-79.21
Cash From Operating Activities	1.097	0.754	1.19	1.639	1.852
Non-Cash Items	4.095	5.844	-9.84	3.806	7.009
Changes in Working Capital	-10.283	-31.787	-30.762	-46.859	-56.719
Cash From Investing Activities	91.649	3.575	-34.963	-0.404	59.391
Capital Expenditures	-3.303	-0.86	-2.265	-0.404	-0.609
Other Investing Cash Flow Items, Total	94.952	4.435	-32.698	0	60
Cash From Financing Activities	-45.246	16.64	45.067	1.309	-5.986
Issuance (Retirement) of Stock, Net	4.426	39.852	4.809	1.309	-5.986
Issuance (Retirement) of Debt, Net	-49.672	-23.212	43.451
Foreign Exchange Effects	0.155	0.501	-0.758	0.067	-1.011
Net Change in Cash	53.614	-11.304	-44.788	-62.864	-26.816
Cash Taxes Paid	0.004	0.035	0.026	0.141	0.413
Cash Interest Paid	6.334	7.074	4.843	5.666	5.795
Financing Cash Flow Items			-3.193

	Dec 2022	Jun 2022	Dec 2021	Jun 2021	Dec 2020
Net income/Starting Line	12.147	-12.209	-6.831	-19.891	-14.722
Cash From Operating Activities	7.056	0.149	-32.02	-27.151	-54.134
Cash From Operating Activities	1.097	0.357	0.754	0.399	1.19
Non-Cash Items	4.095	2.36	5.844	2.705	-9.84
Changes in Working Capital	-10.283	9.641	-31.787	-10.364	-30.762
Cash From Investing Activities	91.649	-2.319	3.575	19.113	-34.963
Capital Expenditures	-3.303	-2.329	-0.86	-0.307	-2.265
Other Investing Cash Flow Items, Total	94.952	0.01	4.435	19.42	-32.698
Cash From Financing Activities	-45.246	-6.764	16.64	26.195	45.067
Issuance (Retirement) of Stock, Net	4.426	-0.165	39.852	38.82	4.809
Foreign Exchange Effects	0.155	0.841	0.501	0.249	-0.758
Net Change in Cash	53.614	-8.093	-11.304	18.406	-44.788
Financing Cash Flow Items					-3.193
Issuance (Retirement) of Debt, Net	-49.672	-6.599	-23.212	-12.625	43.451

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Basilea Company profile

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).

Industry:

Biotechnology & Medical Research (NEC)

Hegenheimermattweg 167b
ALLSCHWIL
BASEL-LANDSCHAFT 4123
CH

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024